Mentor Hyalite dermal filler
This article was originally published in The Gray Sheet
Pivotal study commences of the non-animal stabilized hyaluronic acid dermal filler, comparing the device with Medicis' approved Restylane HA filler. Six-month data from the 12-month study will be submitted in support of a planned PMA application for facial wrinkle correction and lip augmentation. The latter application would be a first for an HA filler. Hyalite includes lidocaine anesthetic to alleviate pain during injection. Mentor acquired the device via its August 2003 acquisition of Vitrolife AB subsidiary A-Life (1"The Gray Sheet" Sept. 8, 2003, p. 19)...
You may also be interested in...
Medicis will hire a 30-40 rep sales force for Q-Med's Restylane non-animal stabilized hyaluronic acid (NASHA)-based surgical wrinkle treatment in time for the product's launch, anticipated by 2004
Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.
With Warp Speed Decisions Already Made, Transitioning To Biden Admin Should Be No Trouble, Slaoui Says
As vaccines near availability, Moncef Slaoui says his full-time role at OWS may be ending. He has not met with the Biden Transition team, but notes that other Warp Speed officials have.